Tracking cancer care: how do real patients fare on common drug combo?
NCT ID NCT04937660
Summary
This study aimed to understand how a specific breast cancer drug combination (palbociclib) is used and how well it works in real-world medical practice across Africa and the Middle East. Researchers observed 185 patients with advanced breast cancer who were already prescribed this treatment by their doctors. The goal was to collect information on treatment patterns, survival, and quality of life to improve future care in these regions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ain Shams University Hospital
Cairo, Egypt
-
Alexandria School of Medicine/Clinical Research Center CRC
Alexandria, Egypt
-
American University of Beirut Medical Center
Beirut, Lebanon
-
Dar El Salam Oncology Hospital
Cairo, 11745, Egypt
-
Hamad Medical Corporation
Doha, Qatar
-
Hammoud Hospital University Medical Center (HHUMC)
Sidon, Lebanon
-
Hôtel Dieu de France (HDF)
Beirut, Lebanon
-
King Fahad Specialist Hospital KFSH-Dammam
Dammam, Saudi Arabia
-
King Hussein Cancer Center
Amman, 11941, Jordan
-
National Cancer Institute
Cairo, 11796, Egypt
-
National Guard Hospital, Riyadh
Riyadh, Saudi Arabia
-
Saint Joseph Hospital - Cancer Centers of Colorado
Jdeidé - Metn, Lebanon
Conditions
Explore the condition pages connected to this study.